Results 121 to 130 of about 15,814 (215)

SGLT2 Inhibition Attenuates Hippocampal Injury and Cognitive Impairment in Adult‐Onset Hypothyroidism

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
Empagliflozin alleviates hypothyroidism‐induced cognitive and locomotor impairments in rats. By suppressing oxidative stress and neuroinflammation, it restores hippocampal CREB/nNOS signaling pathways, reducing anxiety and improving learning and memory deficits caused by propylthiouracil. ABSTRACT Thyroid hormones play a critical role in the maturation
Soner Bitiktaş, Serdar Yiğit, İsa Yeşilyurt, Huseyin Fatih Gul, Orhan Erkan, Başak Gulakar, Zeynep Cansu Aydın, Ali Alper Kahraman   +7 more
wiley   +1 more source

Intermuscular Adipose Tissue as a Multimodality Quantitative Imaging Biomarker: Evidence Across Metabolic, Cardiovascular and Oncologic Diseases

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 4, August 2026.
ABSTRACT Intermuscular adipose tissue (IMAT) refers to adipose tissue located between muscle groups or beneath the muscle fascia, and its accumulation is closely linked to impaired muscle quality, reduced contractile function, and adverse metabolic profiles, establishing it as a core component of myosteatosis.
Feier Ding, Atsushi Nakamoto, Xiaohan Zheng, Toru Honda, Gongzheng Wang, Yuwei Liu, Hideyuki Fukui, Takashi Ota, Masahiro Yanagawa, Noriyuki Tomiyama   +9 more
wiley   +1 more source

The Effect of Empagliflozin on Renal Outcomes in Patients With Established Cardiovascular Disease: Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials. [PDF]

Endocrinol Diabetes Metab
Bahardoust M, Rad FN, Mousavi S, Shamohammadi M, Haghmoradi M, Ghaffari A.   +5 more
europepmc   +1 more source

Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
Cardiovascular disease arises from lifelong accumulation of traditional and emerging risk factors that converge on shared pathophysiological pathways, leading to diverse clinical outcomes, and can be mitigated through integrated screening, prevention, and precision therapies. ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of morbidity
Mowei Kong, Zaiyong Zheng, Min Huang, Shengyu Huang, Xingwei Zhao, Yang Yu, Chunxiang Zhang   +6 more
wiley   +1 more source

Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations. [PDF]

Front Cardiovasc Med
Wang Z, Wang Y, Shangguan W, Li T.
europepmc   +1 more source

Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8697-8701, September 2026.
Min Kyoung Jang, Chang Hee Jung, Han Sol Lee, Areum Lee, Su‐Jin Jeoung, Yong‐Ho Lee, Hae Jin Kim, So Hun Kim, Sung Hoon Yu, Suk Chon, In Kyung Jeong   +10 more
wiley   +1 more source

The Role of Inflammation and Immunity in Cardiovascular Disease: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 8, August 2026.
Inflammation in cardiovascular disease is a dynamic and context‐dependent network rather than a secondary response to injury. Mitochondrial danger signaling links metabolic stress to immune activation through TLR priming, NLRP3 inflammasome amplification, cGAS–STING signaling, and immunometabolic gating, providing a basis for more precise therapeutic ...
Jiaxiang Rong, Zhen Wang, Xiaoxiao Lin, Ziwen Lei, Qianqian Huang, Hang Liu, Fei Luan, Junbo Zou, Yajun Shi   +8 more
wiley   +1 more source

Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Ashraf S, Burhan M, Sarwar S, Ali A, Ahsan A, Ashraf S, Javaid H, Irfan H, Awan MHN, Singh A, Ayalew BD.   +10 more
europepmc   +1 more source

Type 2 Diabetes Mellitus: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 8, August 2026.
This graphical summary illustrates the multiorgan therapeutic landscape for Type 2 diabetes mellitus (T2D), integrating molecular pathogenesis with modern treatment strategies. It depicts how current interventions, including SGLT2 inhibitors, GLP‐1 receptor agonists, and insulin secretagogues, target key organs—kidney, pancreas, gastrointestinal tract,
Shinuan Fei, Xiyue Xiong, Lu Zhang, Jian Zhang, Lawrence W. C. Chan, Hong Jiang, Qingqing Xiong, Changtao Hu, Jie Chen, Sijun Yang   +9 more
wiley   +1 more source

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial. [PDF]

Nat Commun
Liu H, Zhang Y, Feng L, Zhang J, Sun Y, Zhao Y, Jiang M, Liu X, Tracey GJ, Chen L, Liu D.   +10 more
europepmc   +1 more source